Our purpose is
to unlock the full potential of advanced therapies
Dr. Nicole Faust has extensive management experience in the biotechnology sector. Over the last 18 years she has held scientific management positions with Artemis/Taconic Biosciences, amaxa, Lonza, and CEVEC, engaging in the fields of pharmaceutical models, gene transfer, protein production, and gene therapy. She received her Ph.D. from University of Freiburg and an MBA degree from Educatis University, Switzerland.
Chief Executive Officer
Dr. Silke Wissing has wide-ranging experience in the fields of virology, cell biology and cell line development, as well as molecular biology. Before joining CEVEC in 2011, she held a position as a group leader in the Gladstone Institute for Virology and Immunology, San Francisco, where she performed research in the field of HIV-1 biology, stem cell research and cell line development. Dr. Silke Wissing holds a PhD in Biochemistry from the University of Tübingen.
Chief Scientific Officer
Dr. Ulrich Kettling is CBO at CEVEC Pharmaceuticals. Before joining CEVEC in 2018, Dr. Kettling served in various commercial and technical management positions both, in large multinational corporations and in smaller Biotechs, including Clariant; Süd-Chemie; Direvo Biotech. He graduated in Biotechnology and obtained a Ph.D. in Biophysical Chemistry at the Max Planck Institute in Göttingen.
Chief Business Officer
Dr. Nadine Sandhöfer joined CEVEC in 2015. She holds a PhD in human biology with a strong scientific background in tumor biology and in the field of targeted therapies. As a scientist and research manager, Nadine held positions with the Helmholtz Center Munich and the DKFZ Heidelberg. During her position in an ISO certified medical laboratory at the University Hospital Munich, she was trained and certified as quality management representative and internal auditor.
Director QA and Regulatory Affairs
Partner at PEPPERMINTVENTURE PARTNERS
Chairman of the Board
at Creathor Venture
Head of Life Sciences
at NRW Bank Venture Fund
Cofounder of Forbion Capital Partners
Former Life Science Venture Capitalist
Professor at Karlsruhe Institute of Technology
Head of the Institute of Engineering in Life
Section IV: Biomolecular Separation Engineering
Professor and Chair for Cell Culture Technology
University of Bielefeld
Former Associate Director Protein Science
Boehringer Ingelheim Pharma GmbH & Co.KG
Professor at the University of Ulm
and Director of the Department of Gene Therapy
Specialist in gene therapy/vector manufacturing
Professor of Pediatrics
Center for Definitive and Curative Medicine
Stanford University School of Medicine
GAT Holding (Switzerland), CEVEC’s management and further private investors are complementing the investor base of CEVEC Pharmaceuticals GmbH